Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
domingo, octubre 25
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Health Catalyst Inc
HCAT
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.69
-0.05
-2.87%
Últ. Act.: Oct 23, 7:50 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Ganancias:
Beneficios de Q3 2026 dentro de 11 días de ahora en jue nov 5th, después del cierre del mercado
Health Catalyst Financials
Health Catalyst (HCAT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Health Catalyst Shares Tumble Overnight: What Investors Need to Know
Health Catalyst stock fell after hours after reporting Q2 results and issuing weaker third-quarter revenue guidance.
Tanya Rawat
PRO
Health Catalyst Sees FY2026 Sales $246.000M-$249.000M vs $260.780M Est
Health Catalyst (NASDAQ:HCAT) sees FY2026 sales of $246.000 million-$249.000 million vs $260.780 million analyst estimate.
Benzinga Newsdesk
PRO
Health Catalyst Sees Q3 Sales $55.000M-$56.000M vs $62.159M Est
Health Catalyst (NASDAQ:HCAT) sees Q3 sales of $55.000 million-$56.000 million vs $62.159 million analyst estimate.
Benzinga Newsdesk
PRO
Health Catalyst Q2 Adj. EPS $0.04 Beats $0.03 Estimate, Sales $70.487M Beat $69.059M Estimate
Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.03 by 33.33 percent. This is unchanged from the same period last year. The company reported
Benzinga Newsdesk
PRO
Health Catalyst Sees Q2 Sales $68.000M-$70.000M vs $70.752M Est
Health Catalyst (NASDAQ:HCAT) sees Q2 sales of $68.000 million-$70.000 million vs $70.752 million analyst estimate.
Benzinga Newsdesk
PRO
Health Catalyst Q1 Adj. EPS $0.02, Inline, Sales $70.756M Beat $69.171M Estimate
Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The
Benzinga Newsdesk
